|
ApoImmune Awarded $100,000 from Kentucky SBIR-STTR Matching Funds Program
February 1, 2007 (Louisville, KY) - The Kentucky SBIR-STTR Matching Funds Program has awarded ApoImmune, Inc. a $100,000 match for the Company's second year of its National Institutes of Health (NIH) Phase I Small Business Innovation Research (SBIR) grant awarded in September 2006. The two-year NIH grant of $830,000 and newly awarded Matching Funds will be used to develop the Company's lead cancer vaccine ApoVax104. The Phase I SBIR grant was awarded by the National Cancer Institute (NCI).
ApoImmune researchers are working to develop a novel vaccine platform technology, ApoVax104. The first indication for the vaccine will be as a therapeutic vaccine for cervical cancer and human papillomavirus infection (HPV), the virus that causes cervical cancer in women.
The Kentucky SBIR-STTR Matching Funds Program is funded by the Department of Commercialization and Innovation within the Kentucky Cabinet for Economic Development. The Matching Funds Program is designed to award matching funds to for-profit, Kentucky-based companies that have been granted a Federal SBIR or Small Business Technology Transfer (STTR) Phase I or Phase II award for research and technology development. The Kentucky SBIR-STTR Matching Funds are for additional work tasks and activities that support and are complementary to the Federal Award.
"The Matching Funds Program is a tremendous program that will benefit companies within Kentucky with innovative technologies and will also help to attract companies to relocate to the Commonwealth," stated Steven T. Downey, President & CEO of ApoImmune.
About ApoImmune, Inc.
ApoImmune Inc. is a Louisville, Kentucky-based biotechnology company developing novel immunotherapies, which are treatments based on the concept of regulating the immune system to fight disease. The Company's lead immunotherapy is based on the ProtEx technology's ability to teach the immune system to recognize foreign pathogens as harmful and specifically target those harmful cells for destruction. ApoImmune is also developing ProtEx to suppress the immune system in certain cases, which improves current organ and tissue transplant therapies by protecting the transplant from being attacked by the recipient's immune system when transplanted into the body. An added benefit of the ProtEx immune system suppression technology is that it also reduces the need for powerful immunosuppressive drugs with highly toxic effects that are required after transplantation.
For more information, visit www.apoimmune.com.
Certain statements made throughout this press release that are not historical facts contain forward-looking statements regarding the Company's future plans, objectives and expected performance. Any such forward-looking statements are based on assumptions that the Company believes are reasonable, but are subject to a wide range of risks and uncertainties and, therefore, there can be no assurance that actual results may not differ materially from those expressed or implied by such forward-looking statements.
back to Latest News
|
|
|
